InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$458.84

2026-10-16

Market Cap

$99.3B

Volume

1.7M

52-Wk High

$556.52

52-Wk Low

$353.99

Trailing PE

15.3

P/S

1.27

Gross Margin

28.4%

Net Margin

8.8%

ROE

-113%

ROIC

19%

Piotroski

7/9

Altman Z

2.7

1-Yr Return

+9.5%

5-Yr Return

+293.4%

HCA Healthcare, Inc., operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medical and surgical care, encompassing inpatient services, intensive care, cardiac treatment, diagnostic procedures, and emergency services. These hospitals additionally offer a broad range of outpatient care, such as ambulatory surgery, laboratory testing, radiology, respiratory therapy, cardiology, and physical therapy. Beyond its hospital infrastructure, HCA Healthcare operates numerous specialized outpatient facilities. These include standalone ambulatory surgery centers, dedicated emergency care facilities, urgent care clinics, walk-in clinics, advanced diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology treatment facilities, physician practices, and various other healthcare sites. Furthermore, the company oversees psychiatric hospitals, which offer diverse therapeutic programs. These services cater to child, adolescent, and adult psychiatric care, alongside adolescent and adult alcohol and drug abuse treatment and counseling. As of December 31, 2021, HCA Healthcare's extensive portfolio included 182 hospitals, specifically 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals. Its network also featured 125 freestanding surgery centers and 21 freestanding endoscopy centers, all distributed across 20 states and England. Founded in 1968 and formerly known as HCA Holdings, Inc., the company's corporate headquarters are situated in Nashville, Tennessee.

SectorHealthcareIndustryMedical - Care FacilitiesExchangeNYSEMarket Cap$99.3BEmployees320,000 (SEC-filed)CEOSamuel N. HazenIPO2011-03-10CountryUS

One Park Plaza, Nashville, TN 37203 · Tel 615 344 9551 · hcahealthcare.com

INSIDERSTREET SCORE54 / 100Street mean $452.73 (11 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALCOMP-PLAN ACTIVITY ONLYexercises and tax withholding only

1 Year vs S&P 500 · HCA +9.5% · S&P 500 +15.9% · spread -6.4pp

7 Years vs S&P 500 · HCA +293.4% · S&P 500 +189.9% · spread +103.5pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE54of 100

Score Breakdown

Profitability	32/100
Growth	66/100
Momentum	83/100
Quality	60/100
Earnings Quality	70/100
Balance Sheet	29/100
Value	65/100
Risk (safety)	65/100
Overall	53.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
THC	63
EHC	64
DVA	44
UHS	61
ENSG	65
ELV	57
HCA	54

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 60 in 25 Q4, latest 54 — -6 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY54 / 100IS Score 53.6 / 100 · -6.1 from peak of 60

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 76 / 100 · Power +52 · 18 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 54 and price structure at 76 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 53.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 57 → 60 → 58 → 54	the direction matters more than the level
Technical vote share back above 50%	now 91%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,419 → now 1,340	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score2 of 4top 13% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)8 buys2026-09-04

Insider Buys (180d)0none disclosed

ETF Funds (30d)1043 up / 1043 downnet +0 funds

Institutions Added (13F)-79managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,419 · latest 1,340 (-79 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,340	132.4M	$50.3B	59.4%
2026 Q1	1,419	131.4M	$61.3B	59.0%
2025 Q4	1,395	136.3M	$62.8B	61.2%
2025 Q3	1,283	136.8M	$57.8B	61.4%
2025 Q2	1,246	146.7M	$55.4B	65.8%
2025 Q1	1,225	155.2M	$52.6B	69.7%
2024 Q4	1,180	158.8M	$47.1B	71.3%
2024 Q3	1,200	157.9M	$63.3B	70.8%
2024 Q2	1,154	163.7M	$50.9B	73.5%
2024 Q1	1,127	164.1M	$52.5B	73.6%
2023 Q4	1,055	168.2M	$43.9B	75.5%
2023 Q3	996	169.2M	$40.0B	75.9%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value
Schlosser Michael J	EVP and Chief Clinical Officer	2026-09-01	—	1,898	$0.16M
Schlosser Michael J	EVP and Chief Clinical Officer	2026-09-01	—	6,290	$0.64M
Schlosser Michael J	EVP and Chief Clinical Officer	2026-09-01	—	4,400	$0.61M
Schlosser Michael J	EVP and Chief Clinical Officer	2026-09-01	—	2,420	$0.35M
Schlosser Michael J	EVP and Chief Clinical Officer	2026-09-01	—	2,100	$0.36M
Schlosser Michael J	EVP and Chief Clinical Officer	2026-09-01	—	2,370	$0.58M
Schlosser Michael J	EVP and Chief Clinical Officer	2026-09-01	—	4,160	$0.98M
Schlosser Michael J	EVP and Chief Clinical Officer	2026-09-01	—	3,789	$0.96M

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
G — Gifts	1	3,336	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalComp-Plan Activity Only

Open-Market Sells$0.0M0 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-02-18	Michael R Mcalevey	1,694	$0.9M
2026-02-11	Jennifer L. Berres	8,020	$4.1M
2026-02-03	Michael S Cuffe	1,500	$0.7M
2026-02-03	Samuel N. Hazen	42,877	$21.5M
Trailing 12 mo	6 filings	61,819	$31M

Filed	Form	Reporting person	% of class	Shares
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	5.25%	11.7M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2026-02-10	SCHEDULE 13D	Frisco Holding II	17.40%	38.9M sh
2026-02-10	SCHEDULE 13D	Patricia F. Elcan	31.40%	70.2M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
William R. Keating	House	BUY	$15,001 - $50,000	2026-06-30	2026-08-14
Jared Moskowitz	House	BUY	$1,001 - $15,000	2026-06-17	2026-07-27
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-20
David Perdue	Senate	SELL	$15,001 - $50,000	2020-04-14	2021-05-02
David Perdue	Senate	SELL	$15,001 - $50,000	2020-04-14	2021-05-01

House 12-Mo14 trades7 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,419

13F Shares131M59.0% of shares out

New / Closed154 / 104positions, QoQ

Increased / Reduced493 / 553positions, QoQ

Put/Call (13F)1.16option positions

Free Float66.8%145M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Fort Washington Investment Advisor	172,768	$74M
Equitable Trust Co	127,543	$54M
Argent Capital Management Llc	112,176	$48M
Gateway Investment Advisers Llc	63,127	$27M
Wedge Capital Management L L P/Nc	62,812	$27M
Fjarde Ap-Fonden /Fourth Swedish N	60,222	$26M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$1.9B
VTSAX	0.1%	$1.9B
VTI	0.1%	$1.9B
VSMPX	0.1%	$1.9B
VFINX	0.1%	$1.6B
VFIAX	0.1%	$1.6B

13F Filers Holding HCA — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session46.0%2026-10-15

20-Day Avg57.8%50-day 62.9%

TrendFalling20d vs 50d

By Market CenterQ: 44% · N: 71% · B: 35%latest session

Weekly Notional ($B)

Where HCA Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	1.3M	22 sh
Ubsa Ubs Ats	1.2M	24 sh
Sgmt Sigma X2	0.8M	23 sh
Ebxl Level Ats	0.6M	13 sh
Mstx Ms Trajectory Cross (Ats-1)	0.5M	15 sh
Mlix Instinct X	0.5M	31 sh

Where a dollar of HCA Healthcare, Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
American Group	$26.4B	37%
Atlantic Group	$24.7B	34%
National Group	$21.3B	29%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

HCA (live moat model)Peer median: THC · EHC · DVA · UHS · ENSG

Component scores from the live moat model. Peer median illustrative.

Moat score 56/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Samuel N. Hazen	Chief Executive Officer & Director
Jon Mack Foster	Executive Vice President & Chief Operating Officer
Michael A. Marks	Chief Financial Officer & Executive Vice President
Michael R. McAlevey	Executive Vice President and Chief Legal & Administrative Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)4 of 6recent quarters

Avg Surprise+8.2%

Next Report2026-10-27

Income Quality1.63OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+14.0%	+2.5%	+7.9%	+8.7%	+7.1%
Gross profit	+33.3%	-6.5%	+6.3%	+9.6%	+197.5%
Operating income	+33.3%	-6.5%	+6.3%	+9.6%	+13.4%
Net income	+85.3%	-18.9%	-7.1%	+9.9%	+17.8%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	58.8	60.2	65.0	70.6	75.6
Cost of revenue	49.1	51.2	55.3	60.1	44.2
Gross profit	9.7	9.1	9.6	10.5	31.4
R&D expense	0.0	0.0	0.0	0.0	0.0
SG&A expense	0.0	0.0	0.0	31.2	8.0
Operating income	9.7	9.1	9.6	10.5	12.0
EBITDA	14.2	13.3	12.7	13.9	15.6
D&A	2.9	3.0	3.1	3.3	3.5
Pretax income	9.8	8.6	7.7	8.5	9.8
Income tax	2.1	1.7	1.6	1.9	2.1
Net income	7.0	5.6	5.2	5.8	6.8
Diluted EPS ($)	21.16	19.15	18.96	22.00	28.38
Diluted shares (M)	329	295	276	262	231

Operating CF$13B

CapEx$5B

Free cash flow$8B

SBC$0B

Buybacks$10B

Net cash change$-1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.9	0.9	1.9	1.0
ST investments	0.0	0.0	0.1	0.0
Receivables (net)	8.9	10.0	10.8	10.9
Total current assets	13.6	14.9	16.4	13.6
PP&E (net)	27.6	29.9	31.5	31.1
Goodwill + intangibles	9.7	9.9	10.1	10.3
Total assets	52.4	56.2	59.5	60.7
Accounts payable	4.2	4.2	4.3	4.7
Short-term debt	0.4	2.4	4.7	6.7
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	9.9	12.7	15.2	16.4
Long-term debt	37.1	37.2	38.3	41.6
Total liabilities	52.5	55.2	59.0	63.5
Shareholders' equity	-0.1	1.1	0.6	-2.8

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	6.8	5.2	6.7	6.8
D&A	3.0	3.1	3.3	3.5
Stock-based compensation	0.3	0.3	0.4	0.0
Working capital change	(1.2)	(0.5)	(0.1)	0.7
Operating cash flow	8.5	9.4	10.5	12.6
Capital expenditures	(4.4)	(4.7)	(4.9)	(4.9)
Investing cash flow	(3.4)	(5.3)	(4.9)	(5.0)
Buybacks	(7.0)	(3.8)	(6.0)	(10.1)
Dividends paid	(0.7)	(0.7)	(0.7)	(0.7)
Debt issuance / (repay)	3.3	1.3	3.2	3.2
Financing cash flow	(5.7)	(4.1)	(4.6)	(8.6)
Free cash flow	4.1	4.7	5.6	7.7

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	-3853.7%	-305.0%	-230.9%	-269.6%	-159.1%	-113%
ROA	14.2%	10.9%	9.6%	10.0%	11.3%	11.3%
ROIC	22.1%	19.7%	19.4%	20.2%	22.0%	19.4%
Gross margin	16.5%	15.0%	14.8%	14.9%	41.5%	28.4%
Operating margin	16.5%	15.0%	14.8%	14.9%	15.8%	15.5%
Net margin	11.8%	9.4%	8.1%	8.2%	9.0%	8.8%
EBITDA margin	24.2%	22.1%	19.6%	19.7%	20.6%	20.3%
FCF margin	9.2%	6.9%	7.2%	8.0%	10.2%	—
VALUATION
P/E	11.25	11.86	13.79	13.20	15.88	15.3
P/B	-83.91	-24.18	-40.75	-30.44	-17.87	-15.6
P/S	1.33	1.11	1.11	1.08	1.42	1.27
P/FCF	14.55	16.21	15.42	13.49	14.00	16.6
EV/EBITDA	7.98	7.99	8.90	8.58	10.05	9.3
EV/Revenue	1.93	1.76	1.74	1.69	2.07	1.9
Earnings yield	8.9%	8.4%	7.3%	7.6%	6.3%	6.69%
FCF yield	6.9%	6.2%	6.5%	7.4%	7.1%	6.04%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.41	1.38	1.18	1.08	0.83	0.78
Quick ratio	1.21	1.17	1.02	0.97	0.73	0.69
Debt / equity	-39.36	-14.53	-23.60	-18.10	-8.33	-7.42
Debt / assets	72.4%	76.7%	74.5%	76.0%	82.7%	80.6%
Net debt / EBITDA	2.48	2.96	3.22	3.11	3.15	3.02
Interest coverage	7.36	5.93	4.98	5.14	5.37	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	1.20	1.17	1.20	1.22	1.26	1.29
Receivables turnover	7.76	7.09	6.89	6.82	6.99	6.4
DSO (days)	47	51	53	54	52	57
DPO (days)	28	30	28	26	30	31
Cash conversion cycle	34	36	38	39	33	37
GROWTH (YoY)
Revenue growth	14.0%	2.5%	7.9%	8.7%	7.1%	—
Net income growth	85.3%	-18.9%	-7.1%	9.9%	17.8%	—
EPS growth	102.9%	-10.4%	-2.1%	16.7%	30.3%	—
FCF growth	-15.9%	-23.3%	13.6%	20.3%	36.4%	—
PER SHARE ($)
EPS (diluted, TTM)	22.05	19.75	19.33	22.56	29.40	30.70
Book value / share	-2.96	-9.69	-6.54	-9.79	-26.12	-14.10
Revenue / share	186.27	210.85	239.57	276.54	327.68	350.10
FCF / share	17.06	14.45	17.28	22.09	33.34	26.91
Cash / share	4.60	3.18	3.45	7.92	4.51	4.55
SHAREHOLDER RETURN & SCORES
Buyback yield	10.5%	10.5%	5.3%	7.9%	9.3%	10.00%
Altman Z-Score	2.93	2.59	2.52	2.52	2.73	2.7
Piotroski F-Score	6	5	7	6	7	7/9
Beneish M-Score	-2.45	-2.64	-2.74	-2.76	-3.10	-2.64

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	2.7	Grey zone	Grey
Income quality	1.63	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.64	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.69
Interest burden	0.81
Operating margin	15.6%
Asset turnover	1.30×
Financial leverage	-10.95×
= ROE	-125%

Growth Quality (live)	Value
Revenue stability	0.98
Earnings stability	0.40
Earnings persistence	0.94
Revenue CAGR 3y	8.0%
EPS CAGR 3y	14.0%
FCF CAGR 3y	6.7%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield10.00%

Dividend Yield0.67%

Total Shareholder Return10.79%cash yield

SBC / Revenue0.0%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
THC	$21.5B	10.2	53%	14.7%	+5.4%	7/9	+34.2%
EHC	$12.6B	20.6	25%	9.6%	+9.5%	9/9	+4.0%
DVA	$12.0B	16.1	-149%	7.5%	+6.4%	8/9	+49.5%
UHS	$10.9B	7.5	21%	7.7%	+10.0%	8/9	-9.3%
ENSG	$10.3B	26.9	17%	6.9%	+18.9%	7/9	—
ELV	$92.9B	19.0	11%	2.9%	+6.3%	6/9	—
SYK	$113.0B	30.3	17%	19.4%	+8.5%	9/9	—
MRNA	$87.0B	-27.3	-39%	—	-27.2%	2/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

46 Analysts

Str Sell (0)Sell (2)Hold (15)Buy (29)Str Buy (0)

Mean Target (qtr)$452.7311 targets

Target vs. Price-1.3%last-quarter mean

Next Report2026-10-27street $6.66

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$78.50B	$79.12B / $77.92B	$29.50	$30.08 / $29.14	15
FY2027	$81.52B	$82.78B / $80.13B	$32.11	$34.06 / $30.22	16
FY2028	$85.31B	$87.63B / $82.40B	$35.33	$38.40 / $32.85	12

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$495.50	+8.0%	2
Last Quarter	$452.73	-1.3%	11
Last Year	$491.33	+7.1%	54
All Time	$389.49	-15.1%	123

Rolling mean of published targets vs. last close $458.84. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B-

DCF

3/5

ROE

1/5

ROA

5/5

Debt/Eq

1/5

P/E

3/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

HCA +9.5% vs S&P 500 +15.9% — spread -6.4pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$441.00	+17.84	+4.05%	Above
SMA 50	$426.35	+32.49	+7.62%	Above
SMA 200	$444.81	+14.03	+3.15%	Above
EMA 9	$455.11	+3.73	+0.82%	Above
EMA 21	$443.55	+15.29	+3.45%	Above
EMA 50	$429.79	+29.05	+6.76%	Above
EMA 200	$427.80	+31.04	+7.26%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +5218 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%90

Momentum 25%82

Volume 20%56

Volatility 10%100

Patterns 15%50

This Week91% bullishof 11 price-based votes

4 Weeks Ago82%+9 pts since

12 Weeks Ago0%+91 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$441.00

Price vs SMA 50$426.35

Price vs SMA 200$444.81

EMA 9/21 Cross455.1/443.6

SMA 50/200Death

ADX DirectionADX 28

Supertrend$438

Parabolic SAR$439

SMA Slope1.550

RSI62.9

Stochastic K/D81/89

StochRSI K/D82/93

Williams %R-36

CCI117

TSI vs Signal29.5

CMO25.9

ROC7.49%

OBV SignalAccum

Chaikin MF-0.010

MFI71

Force Index1M

Elder Ray Bull29.12

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 89

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$471.55 / $475.81 / $483.13	S1 / S2	$464.23 / $459.97
Bollinger (20,2)	$411.55 – $470.46	Squeeze	Off
52-wk range	$353.99 – $555.69	Off 52-wk high	-17.5%
ATR (14)	$12.34 (2.7%)	Historical vol	25.3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+6.2%Jan73%

+0.7%Feb47%

+1.4%Mar69%

+1.2%Apr47%

+1.9%May53%

+0.9%Jun47%

+4.7%Jul60%

+0.9%Aug60%

+0.5%Sep67%

+1.4%Oct53%

+3.1%Nov60%

+0.7%Dec60%

Sample: 15 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	HCA	S&P 500
Weekly volatility (σ, 1y)	4.35%	1.83%
Best / worst week (1y)	+9.8% / -11.4%	—
Max drawdown (5y, monthly)	-46.8%	—
1-week VaR (95%)	-7.2%	—
Beta (5y)	1.11	1.00

HCA EQUITY WEATHER (LIVE)CLOUDY · +8

Trend+50

Momentum+51

Volume-36

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 188 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+8.4+31.6 vs industry

Trend+49.8+75.8 vs industry

Momentum+51.2+71.4 vs industry

Volume-36.4-11.4 vs industry

Reading	HCA	Medical - Care Facilities n=442	Healthcare n=5,272	All US symbols n=70,435
Overall	+8.4	-23.2	-24.0	-20.5
Trend	+49.8	-26.0	-25.6	-21.3
Momentum	+51.2	-20.1	-28.5	-15.8
Volume	-36.4	-25.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Samuel N. Hazen Chief Executive Officer	$26.5M	53% equity+incentive
Jon M. Foster Executive Vice President and C	$11.0M	41% equity+incentive
Michael A. Marks Executive Vice President an	$10.4M	41% equity+incentive
Michael R. McAlevey Executive Vice President	$5.7M	57% equity+incentive
Michael S. Cuffe, M.D. Executive Vice Presid	$5.7M	56% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	59
Social	56
Governance	64
Composite ESG	60

Composite ESG Trend

Filed	8-K contents	Items
2026-07-29	Financial Obligation; Other Events	2.03,8.01
2026-07-24	Earnings Release; Regulation FD; Other Events; Exhibits	2.02,7.01,8.01,9.01
2026-07-14	Earnings Release; Regulation FD; Exhibits	2.02,7.01,9.01
2026-06-18	Officer/Director Change	5.02
2026-04-30	Material Agreement; Financial Obligation; Other Events; Exhibits	1.01,2.03,8.01,9.01
2026-04-28	Shareholder Vote	5.07
2026-04-27	Other Events; Exhibits	8.01,9.01
2026-04-24	Earnings Release; Regulation FD; Other Events; Exhibits	2.02,7.01,8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-26 to 2026-07-24
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	63 rows · 2006 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-26 to 2026-09-01
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-02-10 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

HCA Healthcare, Inc. (HCA)

Institutions holding — 12 quarters

HCA Healthcare, Inc. (HCA)

Monthly Net Insider Flow (000 shares)

Signal Summary

HCA Healthcare, Inc. (HCA)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding HCA — quarterly

Institutional Put/Call — quarterly

HCA Healthcare, Inc. (HCA)

Where HCA Trades in the Dark

HCA Healthcare, Inc. (HCA)

3.8 · Employees (SEC filings)

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)

Balance Sheet — Full

Cash Flow Statement — Full

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)

Street Price Target — Trajectory

Third-Party Composite Rating

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)

Family Scores (site weights)

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)

HCA Healthcare, Inc. (HCA)